| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Divisions of Biochemical and Clinical Pharmacology [W. T. B., L. R. T.] and Biochemistry [T. J. M.], St. Jude Children's Research Hospital, Memphis, Tennessee 38101
Starting with an established line of human leukemic lymphoblasts (CCRF-CEM), we have developed sublines with varying degrees of resistance to vinblastine by growth in the presence of sublethal concentrations of drug. The resistance of these sublines to vinblastine ranges from 10.6-fold to more than 2000-fold when compared with the sensitive parent cells. These vinblastine-resistant cells tend to form large aggregates in stationary suspension culture, suggesting the possibility of an alteration in the cell surface membrane. The surface glycoproteins of sensitive and vinblastine-resistant CCRF-CEM cells were examined by the galactose oxidase (with or without neuraminidase)-[3H]borohydride procedure. It was found that a glycoprotein with a molecular weight of 170,000 to 190,000 is present on the surface of the drug-resistant cells. This prominent glycoprotein appears to be related to the degree of resistance in that it increases in amount with increased resistance to vinblastine. This relationship obtains with cells up to 269 times more resistant to this drug than is the sensitive parent line. Further increases in the degrees of resistance apparently do not lead to greater amounts of this glycoprotein, suggesting that the changes in the cell surface seen with resistance are not absolute or are not all detectable by the surface-labeling method used in this study. Finally, cells selected for high resistance to 1-ß-D-arabinofuranosylcytosine have a cell surface glycoprotein pattern similar to that of the sensitive parent line, indicating that the altered glycoprotein profile shown here is not a characteristic of resistance in general but is rather associated with resistance to such Vinca alkaloids as vinblastine.
1 Supported by Grants CA-08480, CA-21765, and AM-18106 from the NIH and by American Lebanese Syrian Associated Charities.
2 To whom requests for reprints should be addressed, at Division of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, 332 N. Lauderdale, P. O. Box 318, Memphis, Tenn. 38101.
Received 10/16/78. Accepted 3/ 2/79.
This article has been cited by other articles:
|
|
 |
|
  J. Abraham, M. Edgerly, R. Wilson, C. Chen, A. Rutt, S. Bakke, R. Robey, A. Dwyer, B. Goldspiel, F. Balis, et al. A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine Clin. Cancer Res., May 15, 2009; 15(10): 3574 - 3582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aneja, M. Lopus, J. Zhou, S. N. Vangapandu, A. Ghaleb, J. Yao, J. H. Nettles, B. Zhou, M. Gupta, D. Panda, et al. Rational Design of the Microtubule-Targeting Anti-Breast Cancer Drug EM015. Cancer Res., April 1, 2006; 66(7): 3782 - 3791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Aneja, J. Zhou, S. N. Vangapandu, B. Zhou, R. Chandra, and H. C. Joshi Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011 Blood, March 15, 2006; 107(6): 2486 - 2492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Young, F. M. Rubio, and P. O. Danis A Radioligand Binding Assay for Antitubulin Activity in Tumor Cells J Biomol Screen, February 1, 2006; 11(1): 82 - 89. [Abstract] [PDF]
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia Blood, August 15, 2003; 102(4): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Agrawal, J. Abraham, F. M. Balis, M. Edgerly, W. D. Stein, S. Bates, T. Fojo, and C. C. Chen Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576 Clin. Cancer Res., February 1, 2003; 9(2): 650 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al. Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype Cancer Res., May 1, 2001; 61(10): 4030 - 4037. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. T. Lin, R. Sharma, J. J. Grady, and S. Awasthi A Flow Cell Assay for Evaluation of Whole Cell Drug Efflux Kinetics: Analysis of Paclitaxel Efflux in CCRF-CEM Leukemia Cells Overexpressing P-Glycoprotein Drug Metab. Dispos., February 1, 2001; 29(2): 103 - 110. [Abstract] [Full Text]
|
|
|
|
|
|
L. Jia, M. G. Macey, Y. Yin, A. C. Newland, and S. M. Kelsey Subcellular Distribution and Redistribution of Bcl-2 Family Proteins in Human Leukemia Cells Undergoing Apoptosis Blood, April 1, 1999; 93(7): 2353 - 2359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Belhoussine, H. Morjani, J. M. Millot, S. Sharonov, and M. Manfait Confocal Scanning Microspectrofluorometry Reveals Specific Anthracyline Accumulation in Cytoplasmic Organelles of Multidrug-resistant Cancer Cells J. Histochem. Cytochem., December 1, 1998; 46(12): 1369 - 1376. [Abstract] [Full Text]
|
|
|
|
|
|
C. Ito, R. C. Ribeiro, F. G. Behm, S. C. Raimondi, C.-H. Pui, and D. Campana Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells Blood, February 1, 1998; 91(3): 1001 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. P. Pavelic, J. Reising, L. Pavelic, D. J. Kelley, P. J. Stambrook, and J. L. Gluckman Detection of P-Glycoprotein With Four Monoclonal Antibodies in Normal and Tumor Tissues Arch Otolaryngol Head Neck Surg, July 1, 1993; 119(7): 753 - 757. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Thorgeirsson, B. Huber, S Sorrell, A Fojo, I Pastan, and M. Gottesman Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver Science, May 29, 1987; 236(4805): 1120 - 1122. [Abstract] [PDF]
|
|
|
|
|
|
K. Scotto, J. Biedler, and P. Melera Amplification and expression of genes associated with multidrug resistance in mammalian cells Science, May 9, 1986; 232(4751): 751 - 755. [Abstract] [PDF]
|
|
|
|
|
|
D. Shen, A Fojo, J. Chin, I. Roninson, N Richert, I Pastan, and M. Gottesman Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification Science, May 2, 1986; 232(4750): 643 - 645. [Abstract] [PDF]
|
|
|
|
 |
|
 F. P. ROSENFELT Combination Chemotherapy for Hodgkin's Disease Ann Intern Med, April 1, 1985; 102(4): 554 - 555. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
